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With a reported prevalence of 5-10% and mortality rate of 20-70%, invasive fungal infection is an important complication in allo-hematopoietic SCT (HSCT) recipients. 1, 2 Recent publications have described the serial measurement of serum (1-3)-b-D-glucan levels with the Fungitell assay as a useful tool for early diagnosis of invasive fungal infections in patients receiving conventional chemotherapy. 3, 4 Our experience with two patients receiving prophylactic immunoglobulin replacement during allo-HSCT questions the use of (1-3)-b-D-glucan levels as a screening tool for this patient cohort.
Patient one is a 21-year-old female who received a 2nd HSCT after AML relapse. She developed acute GVHD and with intensive immunosuppressive treatment she was started on immunoglobulin replacement (Baxter Gammagard). Initially, serum (1-3)-b-D-glucan levels were below the detection threshold but subsequently she had a highly positive test result of 366 pg/mL (Figure 1 ). At that time she was afebrile and work-up for invasive fungal infections consisting of blood cultures, galactomannan assay, histoplasma Ag in urine, CT-thorax and ultrasound of the liver was negative. CT of the sinuses did show mucoperiosteal thickening and opacification, but on direct examination no disease was found and sinus cultures were negative. She was receiving nafcillin for a central venous line infection. Because amoxicillin/clavulanic acid treatment is known as a cause for false-positive Fungitell assay results, 5 we tested an aliquot of nafcillin that was negative. Because of a report on immunoglobulin products containing (1-3)-b-Dglucan 6 and one case-report describing normalization of elevated (1-3)-b-D-glucan levels after switching to a different immunoglobulin preparation, 7 an aliquot of the immunoglobulin solution was tested. The result was 190 pg/mL. In addition, serum samples were collected immediately before and after immunoglobulin infusion, with results showing an increase from 127 to 256 pg/mL (1-3)-b-Dglucan level. Test results became negative or equivocal after she did not receive immunoglobulin for 2 weeks. With the restart of immunoglobulin replacement, test results were positive again.
Patient two is a 12-year-old female who received an allogeneic BMT for aplastic anemia after unsuccessful treatment with immunosuppressive therapy. Initially, test results were negative but with weekly immunoglobulin replacement Despite having several test results in the positive or suspicious range, neither of the above reported patients ever met the published definitions 8 for a proven, probable or possible invasive fungal infection. We have shown that all false positive and all but one suspicious test results were reported while our patients were getting immunoglobulin replacement, which is common practice for patients receiving an allo-HSCT. Therefore, serial measurements of (1-3)-b-D-glucan levels are not a useful screening test for this patient cohort while receiving IVIG. However, it should be taken into consideration that not all HSCT patients undergo immunoglobulin replacement therapy, the amount of (1-3)-b-D-glucan in immunoglobulin products varies significantly between manufacturers and among lots of the same brand, 6 and in general, positive results should be critically evaluated.
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